Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

PURPOSE: Sirolimus is the prototypical mammalian target of rapamycin inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including vascular endothelial receptor kinases (VEGFR). These agents have different mechanisms of action providing a strong rationale for combina...

詳細記述

保存先:
書誌詳細
主要な著者: Gangadhar, Tara C., Cohen, Ezra E. W., Wu, Kehua, Janisch, Linda, Geary, David, Kocherginsky, Masha, House, Larry K., Ramirez, Jackie, Undevia, Samir D., Maitland, Michael L., Fleming, Gini F., Ratain, Mark J.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3077032/
https://ncbi.nlm.nih.gov/pubmed/21447721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2061
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料